>What is amazing to me is how long it takes the medical establishment to figure out things like this. It was pretty obvious 5 years ago - and worthy of investigation 10 years ago.<
For AZN, the unfortunate aspect of the delay is that Crestor has already used up five years of its US patent life being a much less consequential drug than it probably could have been.
AZN: Dew/Iwfal: Beyond the obvious implications for coronary outcomes, I wonder if the CRP mitigation affects other bodily systems in a positive manner? This may be quite a revelation in due course.
Market Data 
Markets 
AI
